Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hammam Nevin, Tharwat Samar, Shereef Rawhya R El, Elsaman Ahmed M, Khalil Noha M, Fathi Hanan M, Salem Mohamed N, El-Saadany Hanan M, Samy Nermeen, El-Bahnasawy Amany S, Abdel-Fattah Yousra H, Amer Marwa A, ElShebini Emad, El-Shanawany Amira T, El-Hammady Dina H, Noor Rasha Abdel, ElKhalifa Marwa, Ismail Faten, Fawzy Rasha M, El-Najjar Amany R, Selim Zahraa I, Abaza Nouran M, Radwan Ahmed R, Elazeem Mervat IAbd, Mohsen Wael Abdel, Moshrif Abdel Hafeez, Mohamed Eman F, Aglan Loay I, Senara Soha, Ibrahim Maha E, Khalifa Iman, Owaidy Rasha El, Fakharany Noha El, Mohammed Reem Hamdy A, Gheita Tamer A, Egyptian College of Rheumatology (ECR) COVID-19 Study Group
Аннотация
METHODS: The survey is composed of 25 questions. Some questions were adapted from the global rheumatology alliance COVID-19 survey for patients.
RESULTS: 187 rheumatology staff members across Egypt from 18 universities and authorizations actively participated with a valid response. The mean time needed to complete the survey was 17.7 ± 13 min. Participants were 159 (85%) females (F:M 5.7:1). One-third agreed that they will be vaccinated once available, 24.6% have already received at least one dose, 29.4% are unsure while 16% will not take it. Furthermore, 70.1% agreed that they will recommend it to the rheumatic diseases (RD) patients once available, 24.1% are not sure while 5.9% will not recommend it. RD priority to be vaccinated against COVID-19 in descending order include SLE (82.9%), RA (55.1%), vasculitis (51.3%), systemic sclerosis (39.6%), MCTD (31.6%), Behcet's disease (28.3%). The most common drugs to be avoided before vaccination included biologics (71.7%), DMARDs (44.4%), biosimilars (26.7%), IVIg (17.1%) and NSAIDs (9.1%).
CONCLUSIONS: The results of the study and specifically the low rate of acceptability are alarming to Egyptian health authorities and should stir further interventions to reduce the levels of vaccine hesitancy. As rheumatic disease patients in Egypt were not systematically provided with the vaccine till present, making the vaccine available could as well enhance vaccine acceptance. Further studies to investigate any possible side effects, on a large scale of RD patients are warranted.